AI-generated summary
This open-label pilot study gave nine Alzheimer's disease patients whole-head 810 nm near-infrared therapy over four months. The authors report cognitive score improvements on several measures, with benefits sustained for at least two months, and no device-related adverse effects. They describe the findings as promising but call for larger randomized controlled trials.
- Participants
- 9
- Who or what was studied
- Patients with Alzheimer's disease
- Wavelengths
- 810 nm
- Limits stated in the abstract
- The study is a small, open-label pilot without a control group, and the authors state that larger randomized controlled trials are needed to confirm efficacy.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 810 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Near-infrared, Pilot study, Montreal Cognitive Assessment. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.